NurOwn Benefits Patients With Less Severe ALS, Analyses Show

NurOwn Benefits Patients With Less Severe ALS, Analyses Show

314507

NurOwn Benefits Patients With Less Severe ALS, Analyses Show

A significantly greater proportion of amyotrophic lateral sclerosis (ALS) patients with less severe disease showed slower ALS progression with the investigational cell-based therapy NurOwn relative to a placebo. These are the findings of another post-hoc analysis of data from NurOwn’s Phase 3 clinical trial (NCT03280056), further supporting the potential benefits of Brainstorm Cell Therapeutics’ therapy in patients with earlier stage ALS. Previously, top-line data showed that the therapy failed to meet the main goal of significantly…

You must be logged in to read/download the full post.